Lurasidone solid dispersion and preparation method thereof

Abstract

It relates to a lurasidone solid dispersion and a preparation method, wherein the method comprises melting treatment of a mixture containing lurasidone, a medicinal hot melt carrier, optionally an acidic regulator and plasticizer in order to obtain the solid dispersion described herein, and wherein the lurasidone is provided in a form of free base. The lurasidone solid dispersion obtained by the preparation method according to the example of the invention has the characteristics of high dissolution rate (dissolution rate can reach 30%-70%) in a partial neutral medium (e.g. pH 6.0). The bioavailability of lurasidone solid dispersion increased significantly and the food effect of lurasidone solid dispersion prepared from the example decreased remarkably. It overcomes the limitation of too many medication in the prior art and avoids the reduction of curative effect of the improper medication for the patient or even invalid, ensures the normal efficacy, thereby increases the patient's medication flexibility and compliance.

Description

[0001] priority information [0002] This application claims the priority and rights of the patent application No. 201710009826.8 filed with the State Intellectual Property Office of China on January 06, 2017, and is hereby incorporated by reference in its entirety. technical field [0003] The invention relates to the field of medicine, in particular, the invention relates to a lurasidone solid dispersion, a method for preparing the lurasidone solid dispersion, a pharmaceutical composition, a drug combination and the use of the pharmaceutical composition in preparing medicine. Background technique [0004] Lurasidone hydrochloride is a kind of atypical antipsychotic drug, and on October 28, 2010, the U.S. Food and Drug Administration (FDA) approved the listing of lurasidone hydrochloride tablets of Sumitomo Pharmaceutical Co., Ltd., Japan, with trade name Latuda, specifications There are 20mg, 40mg, 60mg, 80mg, and 120mg / tablet respectively for the treatment of schizophreni...

AI Technical Summary

Problems solved by technology

[0006] However, the bioavailability of lurasidone tablets currently on the market is low, and it must be taken with food at the same time. -The area under the curve (AUC) decreased by 3 times and 2 times respectively, even so the bioavailability is only 9%-19%

However, the medication requirements of this drug are relatively strict for patients with schizophrenia and depression. They usually do not strictly count calories when eating normally, and some patients may have symptoms of refusal to eat or loss of appetite. If they do not eat enough Taking medicine with food may lead to a decrease in the bioavailability of the drug, affecting the curative effect and delaying the patient's condition

Images